STOCK TITAN
  1. Home
  2. News
  3. IPHA

Innate Pharma S.A. ADS - IPHA STOCK NEWS

Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.

Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.

The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.

Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.

The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.

With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.

News

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

Rhea-AI Summary
Innate Pharma announces that its preclinical asset IPH45, a topoisomerase I inhibitor ADC targeting Nectin-4, has been selected for oral presentation at the AACR Annual Meeting 2024. The abstract highlights promising preclinical data showing effective tumor growth inhibition and a favorable safety profile, advancing IPH45 towards clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences clinical trial
-
News

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

Rhea-AI Summary
Innate Pharma SA initiates Phase 1/2 trial for IPH6501, a CD20-targeting tetraspecific NK cell engager for B-cell Non-Hodgkin's Lymphomas. The study aims to enroll up to 184 patients, with the first patient already dosed. IPH6501 co-engages CD20 on malignant B cells and three NK cell receptors, enhancing cytotoxic activity. The IL-2 variant in IPH6501 provides proliferation signals to NK cells, offering a promising alternative to T cell therapies. Dr. Sonia Quaratino and Dr. Lorenzo Falchi express optimism about IPH6501's potential in treating refractory B-cell NHL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
clinical trial
-
News

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Rhea-AI Summary
Innate Pharma (IPH; IPHA) to participate in Leerink Partners Global Biopharma Conference 2024 in Miami, Florida from March 11-13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences
News

Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024

Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at January 1, 2024: Total number of shares outstanding: 80,860,563 ordinary shares, 6,509 Preferred Shares 2016, 7,581 Preferred Shares 2017. Total number of theoretical voting rights: 81,617,753. Total number of exercisable voting rights: 81,599,178.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) announced that the FDA has lifted the partial clinical hold on the lacutamab clinical program. The hold was placed after a patient death in the TELLOMAK study, initially thought to be due to a rare hematologic disorder. The FDA determined the death was related to disease progression and unrelated to the treatment. The lacutamab program continues following positive results in Sézary syndrome and plans to share final data in Mycosis Fungoides.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
News

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) strengthens leadership and corporate governance with the appointment of two new Executive Board members. Hervé Brailly, interim CEO, welcomes Arvind Sood as EVP, President of US Operations, and Dr. Sonia Quaratino as EVP, Chief Medical Officer to the Executive Board. Yannis Morel broadens his remit to Chief Operating Officer. The Company is positioning itself for future success by expanding its footprint in the US market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
management
News

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced that Sanofi has exercised its option to license a natural killer (NK) cell engager program from Innate’s ANKET® platform. Sanofi will be responsible for all development, manufacturing, and commercialization of the program. Innate will receive a €15m payment for the exercise of this option and is eligible for up to €1.35bn in total milestones plus royalties on potential net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
none
-
News

Innate Pharma Announces Leadership Change

Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) CEO Mondher Mahjoubi resigns to join large pharmaceutical company. Hervé Brailly appointed interim CEO. Irina Staatz-Granzer named Chairwoman of the Supervisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
management
-
News

Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

Rhea-AI Summary
Innate Pharma SA (IPHA) and Sanofi are collaborating on SAR443579/IPH6101, a first-in-class NKp46/CD16-based NK cell engager targeting CD123. The drug demonstrated clinical benefit in patients with R/R AML, with 5 complete remissions achieved at 1 mg/kg and was well tolerated up to doses of 6 mg/kg. The updated efficacy and safety results were shared at the American Society of Hematology 2023 Annual Meeting, showing promising durable clinical efficacy with a favorable safety profile in various blood cancers. SAR443579 has FDA Fast Track Designation for the treatment of acute myeloid leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
clinical trial
News

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome patients. The global confirmed objective response rate (ORR) was 37.5%, with a median progression-free survival of 8.0 months. Lacutamab showed robust clinical activity and an overall favorable safety profile, with a virtual KOL event scheduled for Tuesday, December 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of Innate Pharma S.A. ADS (IPHA)?

The current stock price of Innate Pharma S.A. ADS (IPHA) is $1.67 as of January 23, 2025.

What is the market cap of Innate Pharma S.A. ADS (IPHA)?

The market cap of Innate Pharma S.A. ADS (IPHA) is approximately 144.2M.

What does Innate Pharma S.A. specialize in?

Innate Pharma S.A. specializes in immuno-oncology, developing therapeutic antibodies to enhance the innate immune system's ability to fight cancer.

What are some of Innate Pharma's key products?

Key products include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501.

How does Innate Pharma generate revenue?

The company generates revenue through research collaborations, licensing agreements, and milestone payments from pharmaceutical companies.

Who are some of Innate Pharma's notable partners?

Innate Pharma collaborates with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.

What is ANKET?

ANKET stands for Antibody-based NK cell Engager Therapeutics, Innate Pharma's proprietary platform for developing innovative cancer treatments.

What is the focus of Innate Pharma’s current projects?

Current projects focus on developing first-in-class antibodies and checkpoint inhibitors to address various cancer indications.

What stage is Innate Pharma in?

Innate Pharma is in the clinical stage, advancing multiple therapeutic candidates through clinical trials.

What makes Innate Pharma's approach unique?

Their unique expertise in natural killer cell biology and checkpoint inhibitors sets them apart in the field of immuno-oncology.

What is immuno-oncology?

Immuno-oncology is a field of cancer treatment that uses the body's immune system to detect and kill cancer cells.

How does Innate Pharma contribute to cancer research?

Innate Pharma contributes through innovative research and development of new therapies that harness the immune system to treat cancer.
Stock IPHA logo
Innate Pharma S.A. ADS

Nasdaq:IPHA

IPHA Rankings

#4165 Ranked by Market Cap
N/A Ranked by Dividends

IPHA Stock Data

144.16M
82.80M
0.5%
1.1%
Biotechnology
Healthcare
Link
United States of America
Marseille